Please assess the completion status of the following clinical trial:

Trial Title: Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects whose LDL-C is not controlled by a stable dose of atorvastatin (Population A).~* Subjects who are naïve to a treatment by lipid lowering drug and whose LDL-C is not controlled (Population B).~Exclusion Criteria:~* Severe acute or chronic medical or psychiatric condition or laboratory abnormality.~* Pregnant females; breastfeeding females; males and females of childbearing potential; males and females of childbearing potential who are unwilling or unable to use a highly effective method of contraception.~* Subjects who were administered or prior exposed to PF-04950615 and/or anti-body targeting PCSK9.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Population A (Type: EXPERIMENTAL): A total of 9 groups in two population. Population A comprises hypercholesterolemic Japanese subjects whose LDL-C is not controlled by a stable dose of atorvastatin. A subject who is receiving a stable dose of atorvastatin will be randomized into one out of 5 dose groups.
- Population B (Type: EXPERIMENTAL): A total of 9 groups in two population. Population B comprises hypercholesterolemic Japanese subjects who are naïve for a treatment by lipid lowering drug and whose fasting LDL-cholesterol is not controlled. A subject who is treatment naïve will be randomized into one out of 4 dose groups.

Based on this trial design, predict the completion outcome and termination type (if applicable).